Evidence map›Paper›PMID 40618217›Full record

ArticleAnnals of medicine2025

Evaluation of serum hsa_tsr014055 as a potential biomarker for diagnosis and prognosis of hepatocellular carcinoma.

Jing Xu, Bairong Chen, Jing Qi, Jinran Wu, Wei Feng, Kangfeng Jin, Hongyi Bao, Lin Chen, Feng Wang

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07265271 (Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07265271 recruitingnot on this map

Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)

TypeobservationalSponsorCity of Hope Medical CenterRan2025 to 2028Enrolled600ConditionsHepatocellular Carcinoma (HCC)ArmsSmall RNA sequence, Rt-qPCR
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jing XuResearch Center of Clinical Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
Bairong ChenResearch Center of Clinical Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
Jing QiResearch Center of Clinical Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
Jinran WuResearch Center of Clinical Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
Wei FengResearch Center of Clinical Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
Kangfeng JinResearch Center of Clinical Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
Hongyi BaoResearch Center of Clinical Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
Lin ChenNantong Institute of Liver Diseases, Nantong Third People's Hospital Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.
Feng WangResearch Center of Clinical Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.ORCID 0000-0002-4721-1062

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMounting evidence has shown that tRNA-derived small RNAs (tsRNAs) play critical roles in the progression of tumors, including hepatocellular carcinoma (HCC). Nevertheless, the clinical values of serum tsRNAs for HCC are still largely unknown.

methodsSerum samples were procured from 153 HCC patients, 93 hepatitis cases, and 89 healthy donors from the Affiliated Hospital of Nantong University. A series of analyses, including qRT-PCR, receiver operating characteristic (ROC) curve, and Kaplan-Meier analysis, were performed to investigate the potential performance of serum tsRNA-Val-5-0035, also known as hsa_tsr014055, for HCC clinical practice.

resultsMethodological evaluation showed that qRT-PCR detection of serum hsa_tsr014055 had better stability, repeatability, and primer specificity. Moreover, serum hsa_tsr014055 was significantly higher in HCC patients than in hepatitis cases and healthy donors. Dynamic monitoring disclosed that it was dropped in HCC patients who had undergone surgery. Besides, it was positively correlated with TNM stage, differentiation grade, and microvascular invasion, as well as the prognosis of HCC patients. Additionally, serum hsa_tsr014055 had potential diagnostic value for HCC. Importantly, when it was combined with alpha-fetoprotein (AFP) and des-γ-carboxyprothrombin (DCP), the diagnostic efficacy was obviously improved. Also, bioinformatic prediction demonstrated that hsa_tsr014055 had 717 downstream targets, which were enriched in Hedgehog and cAMP signaling pathways.

conclusionSerum hsa_tsr014055 may be a promising biomarker in the diagnosis, evaluation of therapeutic effects, and assessment of HCC prognosis. Especially when serum hsa_tsr014055 was combined with AFP and DCP, the diagnostic efficacy for HCC would be enhanced.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularLiver NeoplasmsAdultAgedCase-Control StudiesFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPrognosisROC CurveBiomarkers, TumorbiomarkerdiagnosisHepatocellular carcinomahsa_tsr014055tRNA-derived small RNAs

Identifiers

PMID40618217
PMCPMC12231276

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.